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Introduction
Counseling parents of a fetus with trisomy 13 mosaicism
remains difficult because of the phenotypic variability
associated with the condition; some patients exhibit
the typical phenotype of complete trisomy 13 with neo-
natal death, while others have few dysmorphic fea-
tures and prolonged survival. This article provides a
comprehensive review of the prenatal diagnosis and
genetic counseling for mosaic trisomy 13, including
confined placental mosaicism (CPM)13, mosaic trisomy
13 diagnosed at amniocentesis, and phylloid hypome-
lanosis in association with mosaic trisomy 13.
Confined Placental Mosaicism 13
CPM occurs when there is a cytogenetic discrepancy
between the extraembryonic and embryonic tissues.
True chromosome mosaicism appears in both placen-
tal and fetal cells, whereas CPM appears only in the
placenta. [1]. CPM has been detected in 2% of viable
pregnancies at 10–12 weeks’ gestation [1–3]. Kalousek
et al [4,5] suggested the existence of three types of
CPM: (1) type I CPM with mosaic or nonmosaic aneu-
ploidy in the cytotrophoblasts, normal diploidy in 
the chorionic stroma and normal diploidy in the
embryonic/fetal tissues; (2) type II CPM with normal
diploidy in the cytotrophoblasts, mosaic or nonmo-
saic aneuploidy in the chorionic stroma and normal
diploidy in the embryonic/fetal tissues; and (3) type III
CPM with mosaic or nonmosaic aneuploidy in the
cytotrophoblasts, mosaic or nonmosaic aneuploidy in
the chorionic stroma and normal diploidy in the
embryonic/fetal tissues.
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CPM can affect placental function and has been
reportedly associated with a significant increase in
perinatal loss, spontaneous abortion, and intrauterine
growth restriction [5–9]. Robinson et al [10] found that
meiotic origin of the extra chromosome in the placenta
was highly correlated with type III CPM and an increased
risk of pregnancy complications, whereas mitotic ori-
gin was highly correlated with types I and II CPM and a
lower risk of pregnancy complications.
In a United States collaborative study on chorionic
villus sampling (CVS), Ledbetter et al [2] found 13 cases
of mosaic trisomy 13 among 11,473 cases of CVS.
Nine were identified from direct preparations only and
the other four from cultures only. Among these 13 cases,
nine were considered to be CPM13 with normal preg-
nancy outcomes, and the other four were terminated
with undetermined cytogenetic interpretations. Smidt-
Jensen et al [11] reported one case of CPM13 with
normal outcome among 2,928 CVS samples. In a study
of 2,612 consecutive cases of CVS, Wang et al [8]
found CPM in 51 cases (1.9%) of which trisomies 2, 7,
8 and 13, and sex chromosome abnormalities were 
the most frequently encountered aneuploidies. These
included two cases of trisomy 13 type I CPM and one
case of trisomy 13 type III CPM. Fryburg et al [12]
reported one case of true mosaic trisomy 13 detected by
CVS among 20 cases of true mosaicism in 1,724 CVS
procedures. Pittalis et al [13] reported three cases of
CPM13 with normal outcomes among 4,860 cases of
CVS. Roland et al [14] reported one case of CPM13
with normal pregnancy outcome among 27 cases of
CPM identified in 3,258 CVS procedures. Wang et al
[15] reported five cases of mosaic trisomy 13 among
4,000 consecutive cases of CVS. In three of these cases,
the trisomy 13 cell line was detected in direct prepara-
tions but not by culture, and the fetal outcomes were
normal. The fourth case had mosaicism for i(13q) also
identified in direct preparations but not by culture, and
a normal karyotype was recorded at follow-up amnio-
centesis. The fifth case had mosaicism for trisomy 13
and trisomy 7 and were identified in direct prepara-
tions and culture, but not at follow-up amniocentesis.
In a major review by the European Collaborative
Research on Mosaicism in CVS reported by Hahnemann
and Vejerslev [16], 15 cases of mosaic trisomy 13 were
identified from 92,246 CVS procedures. CPM13 was
found in 13 cases and true fetal mosaicism in two cases.
Delatycki et al [17] reported two cases of CPM13. In the
first case, trisomy 13 was identified in all 10 cells
examined in short-term CVS culture and in 15 cells in
long-term CVS culture, as well as in 30 of 35 cells in
additional long-term CVS culture. The pregnancy was
terminated, but the fetal skin fibroblasts revealed a
normal karyotype in 50 cells. In the second case, trisomy
was identified in 9 of 30 cells in long-term CVS culture.
Follow-up amniocentesis revealed a normal karyotype;
the results of ultrasound were normal, and a normal
baby was born at term. Los et al [18] reported three
cases of CPM13 out of 3,499 semi-direct chorionic villus
preparations with low mosaicism for trisomy 13, such as
47,XY,+13[3]/46,XY[27], 47,XX,+13[2]/46,XX[28] and
47,XY, + 13[2]/46,XY[28], respectively. The karyotypes
were normal at amniocentesis, and the pregnancy out-
comes were also normal in all these cases. In a study of
6,820 CVS cases, Schuring-Blom et al [19] found one
false-positive result out of 13 cases of full trisomy 13 in
cytotrophoblasts and two false-positives in three cases of
mosaic trisomy 13 in cytotrophoblasts. Schuring-Blom
et al [19] suggested that the diagnosis of trisomy 13 in
cytotrophoblasts should be confirmed in other tissues,
unless fetal abnormalities were seen at ultrasound, and
that follow-up amniocentesis was advisable if mosaicism
was detected at CVS. In contrast, Kalousek et al [4]
only detected diploid cells in the cytotrophoblasts of
some pregnancies with viable trisomy 13 conceptions, and
suggested that direct preparations of CVS were unreli-
able for the prenatal diagnosis of trisomy 13 and that
long-term villus cultures should be used. Doray et al [20]
reported CPM13 associated with body wall complex in
a fetus. In this case, direct chromosome analysis in chori-
onic villi showed a 47,XY, + 13[20]/46,XY[1] karyotype,
while long-term chorionic villus culture, post-mortem
chromosome analysis of skin fibroblasts, and fluores-
cence in situ hybridization of fetal renal and hepatic 
tissues revealed a 46,XY karyotype.
When the abnormal cell line comprises at least 15%
of the whole sample, then quantitative fluorescence
polymerase chain reaction (QF-PCR) can detect mosai-
cism [21]. Discrepancies between QF-PCR results from
uncultured CVS samples and karyotyping results from
long-term cultured CVS samples have been reported
[21–26]. Most discrepancies can be attributed to
mosaicism. Three such cases of CPM13 detected by
QF-PCR have been described [21,26]. Donaghue et al
[21] reported a difference in results between prenatal
uncultured and cultured CVS samples in two cases,
where uncultured villus samples revealed mosaic trisomy
13 by QF-PCR, but cultured villus samples tested by
QF-PCR and/or karyotype analysis revealed normal
results. Lau et al [26] reported discrepant findings
between QF-PCR in uncultured CVS samples and karyo-
typing of long-term cultured CVS samples in one case;
mosaic trisomy 13 was detected by QF-PCR and a nor-
mal karyotype was detected by karyotyping. The baby
was delivered at 39 weeks of gestation with no obvious
abnormalities. Lau et al [26] suggested that in case of
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discrepant results, CPM should be confirmed by amnio-
centesis, which is able to provide a better representation
of the fetal lineage.
Mosaic Trisomy 13 Diagnosed at
Amniocentesis
Multiple cell lines with different chromosome consti-
tutions may be found in amniotic fluid cell cultures.
Mosaicism with a single abnormal cell (level I mosaicism)
is referred as pseudomosaicism and has no clinical sig-
nificance. Mosaicism in which two or more cells with
the same aberration are found in a single flask/colony
(level II mosaicism) is usually referred as pseudomo-
saicism and of in vitro clonal origin. However, a true
fetal chromosomal abnormality may exist in ≤1% of
cases with level II mosaicism [2,12,27–29]. Mosaicism
with two or more cells with the same aberration found
in multiple flasks/colonies (level III mosaicism) is usually
referred as true fetal mosaicism or simply as mosaicism
[27,30,31].
In a study of chromosome mosaicism in 6,000
amniocentesis samples, Wilson et al [32] found level II
mosaicism in 0.92% of amniocenteses and level III
mosaicism in 0.2%. In a study of chromosome mosa-
icism in 22,000 amniocenteses, Hsu et al [33] found
true chromosome mosaicism in 50 cases (0.27%),
including two cases of mosaic trisomy 13. Hsu et al
[34] found chromosome mosaicism in 555 of 179,663
amniocenteses (0.3%). Robinson et al [35] found that
the majority of cases of mosaic trisomy 13 were associ-
ated with trisomic fertilization compatible with a meiotic
origin of the extra chromosome and with postzygotic
loss of one chromosome.
Hsu et al [33] and Hsu and Benn [36] recommended
guidelines for the management of cases with suspected
amniocyte mosaicism. Suspected amniocyte mosaicism
for trisomy 13 in a single cell (single flask), multiple
cells (single flask), single colony (single dish) or multi-
ple colonies (single dish) requires extensive work-up. In
the case of the flask method, this includes examina-
tion of 10 additional cells from the second flask where
the first 10 cells shows only normal chromosomes, and
analysis of 20 cells from a third primary culture [33].
Work-up for the in situ method includes examination of
a total of 24 colonies from multiple in situ culture ves-
sels, not including the number of colonies from the ini-
tial culture dish in which an abnormal colony or
several abnormal colonies were detected [33]. Since
there is considerable diversity in the clinical features of
fetuses diagnosed with mosaic trisomy 13 at amniocen-
tesis, high-resolution ultrasonography is very helpful
for guiding the genetic counseling of women who elect
to continue an affected pregnancy. Confirmatory cyto-
genetic analyses, such as repeat amniocentesis, placen-
tal analysis, cord blood sampling and analysis of cord
fibroblasts, may also be helpful.
Malin et al [37] reported one case of level I mosaic
trisomy 13 and two cases of level II mosaic trisomy 13
diagnosed by amniocentesis, each of which had a nor-
mal outcome and a normal karyotype after birth. Fejgin
et al [38] reported prenatal diagnosis of mosaic trisomy
13 in a fetus in which trisomy 13 was detected in 4 of
10 amniocytes (40%) and 1 of 160 cord blood lympho-
cytes. Ultrasonography revealed an apparently normal
fetus, but the pregnancy was terminated electively. The
abortus had a normal phenotype, and cytogenetic analy-
sis of the kidney, diaphragm, lung, blood from the heart,
skin and placenta revealed a normal karyotype. In a
major review of autosomal trisomy mosaicism diagnosed
in amniocytes, Hsu et al [33] documented 15 cases of
mosaic trisomy 13, and five of the 11 cases were known
to have abnormal phenotypes. Delatycki and Gardner
[47] reported two cases of prenatally diagnosed low-
level trisomy 13 mosaicism with normal outcomes. In
the first of these cases, amniocentesis revealed level II
mosaicism of 47,XX, + 13/47,XX, + 22/46,XX with one
in situ culture showing 46,XX in all cells, one dispersed
culture showing 47,XX, + 13 in 7 of 50 cells, and one
dispersed culture showing 47,XX, + 22 in 5 of 50 cells.
Subsequent fetal blood sampling revealed a 46,XX
karyotype in 100 of 100 lymphocytes. A normal baby
was delivered with no dysmorphic features except for
an atrial septal defect. A cord blood sample at birth
showed 47,XX,+13 in 3 of 100 lymphocytes. The child
was entirely normal at age 3 years 6 months. In the sec-
ond case, CVS revealed trisomy 13 in 7 of 20 cells in
long-term culture and in 33 of 50 cells in the second
culture. Follow-up amniocentesis revealed trisomy 13
in 1 of 28 colonies in an in situ study and in 1 of 400
lymphocytes at cordocentesis. A normal baby was
delivered and postnatal cord blood sampling revealed
trisomy 13 in 1 of 150 lymphocytes, 2 of 32 amnion
cells, 0 of 27 smooth chorion cells, 1 of 30 cord inser-
tion villi cells, and 3 of 30 placental margin villus cells.
The child was normal at age 17 months. Delatycki et al
[17] also reported two cases of level II mosaic trisomy
13 diagnosed at amniocentesis, each of which had a
normal outcome and a normal karyotype after birth.
Eubanks et al [39] reported prenatal diagnosis of mosaic
trisomy 13 based on second-trimester amniocyte cul-
tures in which nine colonies (68%) had a 47,XX, + 13
karyotype and six colonies (32%) had a 46,XX kary-
otype. Prenatal ultrasound was normal, and postmortem
examination was also normal, with the exception of a
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small ventricular septal defect and low-set ears. Chro-
mosomal studies from two cultures of fetal pericardium
confirmed mosaic trisomy 13 with trisomy 13 in 2 of
10 cells (20%). Wallerstein et al [40] documented an
abnormal outcome in 10 of 25 cases of mosaic trisomy
13 diagnosed by amniocentesis (40%). The 10 abnormal
cases were abortuses including five with multiple con-
genital anomalies, two with intrauterine growth restric-
tion, and three with intrauterine death (one with a
congenital heart defect and one with hydrops). They
found that in 15 cases with < 50% trisomy 13 cells,
there was a 26.7% (4/15) risk of abnormalities, whereas
in 10 cases with > 50% trisomy 13 cells, there was a 60%
(6/10) risk of abnormalities. They also found that in
cases with an abnormal outcome, the mean percentage
of trisomy 13 amniocytes was 58% (range, 6–94%),
whereas in cases with a normal liveborn, the mean per-
centage of trisomy 13 amniocytes was 9.3% (range,
5–13%). Phelan et al [41] reported second-trimester
diagnosis of mosaicism for trisomy 13 and triploidy in
amniocyte cultures, of which 12 of 16 colonies from 
in situ culture were trisomy 13, and 4 of 16 colonies were
triploid. The fetus had multiple congenital anomalies
including intrauterine growth restriction, syndactyly,
polydactyly, facial dysmorphism, and a scalp defect.
The mosaicism was postnatally confirmed in cord
blood, skin, and placenta. Chen et al [42] reported
second-trimester diagnosis of mosaicism for trisomy 
13 by amniocentesis in a case where mosaic trisomy
13 was detected in two separate amniocyte cultures
with mosaicism for trisomy 13 in 5 of 16 (31.3%) and
3 of 20 cells (15%), respectively. Ultrasonography re-
vealed an apparently normal fetus, but the fetus was
terminated electively. The abortus had a normal phe-
notype. Polymorphic DNA marker analysis confirmed
mosaic trisomy 13 in the samples of cord blood and
umbilical cord, and trisomy 13 in the samples of pla-
centa. Chen et al [43] also reported postnatal cytoge-
netic diagnosis of mosaicism for trisomy 13 in a fetus
with holoprosencephaly and cystic hygroma. In that
case, trisomy 13 was detected in 17 of 40 chorionic vil-
lus cells (42.5%), and polymorphic DNA marker analy-
sis of the samples of fetal skin and placenta confirmed
mosaic trisomy 13.
However, even pregnancies with a high percentage
of trisomy 13 cells detected at amniocentesis may
result in a relatively mild phenotype [44], or even a
normal outcome [45]. Chen et al [44] reported an
unusual case of mosaic trisomy 13 with a high per-
centage of trisomy 13 cells at amniocentesis but with
relatively mild phenotypic abnormalities at birth. In
that case, CVS showed a 46,XX,der(13;13)(q10;q10)
karyotype. Subsequent amniocentesis and cordocentesis
showed mosaic trisomy 13 with a 46,XX,der(13;13)
(q10;q10)[24]/46,XX[7] karyotype on the first amniocyte
culture, a 46,XX,der(13;13) (q10;q10)[36]/46,XX[10]
karyotype on the second amniocyte culture, and a
46,XX,der(13;13)(q10;q10)[14]/46,XX[86] karyotype
on fetal cord blood culture. The percentages of tri-
somy 13 cells in the blood lymphocytes at birth, 2 days
old, 1 month old and 6 months old were 54%, 14%,
0% and 0%, respectively. Cytogenetic analysis of skin
and cardiac tissue at 6 months revealed a normal karyo-
type. The baby had only a few structural abnormali-
ties, including low-set ears, absence of the 12th rib,
and a ventricular septal defect. Development was nor-
mal at the age of 8 months. Di Giacomo et al [45]
additionally reported prenatal diagnosis of mosaic 
trisomy 13 with a high percentage of trisomy 13 cells
and a normal outcome. In their case, second-trimester
amniocentesis showed trisomy 13 in 24 of 34 amnio-
cyte clones (70.6%). Subsequent cord blood sampling
and CVS showed trisomy 13 cells in 10 of 100 blood
lymphocytes (10%), and in 11 of 11 cells in short-term
culture (100%) and in 13 of 13 in long-term culture of
CVS (100%). Neonatal cord blood analysis revealed a
47,XX, + 13[11]/46,XX[96] karyotype, and peripheral
blood analysis at 2 years of age revealed a 47,XX, +
13[18]/46,XX[96] karyotype. Examination of buccal
mucosal cells, skin fibroblasts and urinary tract cells
using interphase fluorescence in situ hybridization re-
vealed that the percentages of cells with three chromo-
some 13 signals were 0% (0 of 103 cells), 5% (29 of 575
cells) and 23% (13 of 56 cells), respectively. The child was
normal with no dysmorphic features at age of 2 years.
Mosaic trisomy 13 has rarely been recognized.
Magenis et al [46] proposed that mosaic trisomy 13
occurs in only 5% of all trisomy 13 cases. Patients with
mosaic trisomy 13 usually have a longer survival and a
less severe phenotype, with a wide variation from essen-
tially normal to grossly abnormal, according to the tissue
distribution of the trisomy 13 cells [47,48]. The per-
centage of abnormal cells decreases with age, possibly
because of natural selection against the trisomy 13
cells [44,47,49]. Individuals with mosaic trisomy 13
and an essentially normal phenotype may be fertile,
and should be aware of the theoretical risk of gonadal
mosaicism and the production of offspring with nonmo-
saic trisomy 13. In a literature review of 49 published
cases, Griffith et al [50] found phenotypic variability
in trisomy 13 mosaicism, with some patients having
the typical phenotype of complete trisomy 13 with
neonatal death and others having few dysmorphic fea-
tures and prolonged survival, thus making its clinical
diagnosis difficult. Griffith et al [50] also found that
there was no clear correlation between the percentage
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of trisomy 13 cells and the level of intellectual func-
tion, and that the most commonly associated malfor-
mations were ear anomalies, cleft lip and palate, and
congenital heart defects.
The Table summarizes the clinical details of reported
cases of mosaic trisomy 13 diagnosed by amniocente-
sis. The spectrum of phenotypic variations in cases with
prenatally detected mosaic trisomy 13 is broad. There-
fore, genetic counseling of parents of fetuses with pre-
natally detected mosaic trisomy 13 remains difficult
and further studies are needed to identify the indicators
associated with favorable outcome.
Mosaic Trisomy 13 and Phylloid
Hypomelanosis
Phylloid hypomelanosis is a distinct form of pigmentary
mosaicism characterized by hypochromic lesions with
various elements, including round or oval patches and
oblong macules arranged in such a way as to resemble
the leaves of a begonia (Greek phyllom= leaf, eidos= form)
[51]. Phylloid hypomelanosis is known to be associated
with mosaic trisomy 13 [52–57]. In a review of six cases
of phylloid hypomelanosis, Happle [54] reported that
five had mosaic trisomy 13 and that skin fibroblasts
showed chromosome mosaicism in four out of these five
patients. Happle [54] suggested that phylloid hypome-
lanosis mainly originates from a mosaic state involving
chromosome 13. González-Enseñat et al [58] reported
mosaic partial trisomy 13 in two girls with mental defi-
ciency and phylloid hypomelanosis. One patient showed
mental deficiency, phylloid hypomelanosis, syndactyly,
clinodactyly, trichomegaly of the eyelashes, low frontal
hairline and several pale pink telangiectatic macules,
while her blood lymphocytes showed a 46,XX karyo-
type, and fibroblasts derived from the lesional skin
demonstrated tetrasomy of 13q21–qter. The second
patient showed mental deficiency, phylloid hypome-
lanosis, epileptic seizures, dental malposition, oligodon-
tia, preauricular fistulas, scoliosis, tethered cord, and
syringomyelia. Her blood lymphocytes showed a 46,XX
karyotype, and fibroblasts derived from the lesional
skin demonstrated trisomy of 13q22–qter. González-
Enseñat et al [58] suggested that phylloid hypome-
lanosis is a distinct clinicogenetic entity that is most
likely related to the 13q region. Dhar et al [59] reported
an 8-year-old girl with phylloid hypomelanosis and
precocious puberty. The girl was found to have mosai-
cism for tetrasomy 13q in the form of inverted
dup(13)(q21) in skin fibroblasts and peripheral blood
lymphocytes. Dhar et al [59] suggested that mosaic
overexpression of the candidate pigmentary genes such
as endothelin receptor type B (EDNRB), which is respon-
sible for melanoblast migration, may cause impaired
melanoblast migration and melanocyte formation, lead-
ing to phylloid hypomelanosis and depigmentation.
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